Thrombocytopenia is a condition in which blood platelets are low in person’s body. Thrombocytes are colourless blood cells that help blood clot. Thrombocytopenia is common in cancer patients. The occurrence of chemotherapy-induced thrombocytopenia varies from person to person depending on the treatment used. Each chemotherapy agent differs in how it causes thrombocytopenia. Mostly chemotherapy-induced thrombocytopenia are caused by the gemcitabine-and platinum-based regimens used in chemotherapy. Alkylating agents affect stem cells, cyclophosphamide affects later megakaryocyte progenitors, bortezomib prevents platelet release from megakaryocytes, and some treatments promote platelet apoptosis. Thrombocytopenia can also occur with any infection or adverse drug reaction associated with cancer treatment. Chemotherapy-induced therapy can be particularly harmful, as it can delay chemotherapy, decrease the dose of chemotherapy drugs, increase medical expenses, and can cause induced bleeding.
Market Dynamics
The increasing number of cancer cases is expected to surge the number of chemotherapy procedures, and this is expected to drive the Euopean chemotherapy-induced thrombocytopenia therapeutics market. For instance, according to the World health Organization (WHO), over 3.7 million new cancer cases and 1.9 million death occur each year, and cancer represents the second most important cause of death and morbidity in 2012 in Europe, on a global scale, cancer accounted for 8.2 million deaths Currently, there are no approved treatments available for (chemotherapy-induced thrombocytopenia) CIT in the European Union.
However, growth of the global chemotherapy-induced thrombocytopenia therapeutics market is expected to be hampered over the forecast period, owing to discontinuation of clinical trials due to failure of chemotherapy-induced thrombocytopenia therapeutics. For instance, in October 2020, Swedish Orphan Biovitrum AB announced results of its phase III study of Avatrombopag (Doptelet), an oral thrombopoietin (TPO) receptor agonist, in solid tumor cancer patients with chemotherapy-induced thrombocytopenia (CIT). The study failed to meet the primary end point of avoiding platelet transfusions chemotherapy dose reductions by 15% or greater and also failed to show efficacy in chemotherapy-induced thrombocytopenia.
Key features of the study:
- This report provides in-depth analysis of the global chemotherapy-induced thrombocytopenia therapeutics market size (US$ 1,866.4 Mn) by 2027, and compound annual growth rate (CAGR) 5.0% for the forecast period: 2020-2027, considering 2019 as the base year.
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players.
- It profiles key players in the global chemotherapy-induced thrombocytopenia therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Amgen, Inc., Novartis AG., Pfizer Inc., LLC, Swedish Orphan Biovitrum AB., Jiangsu HengRui Medicine Co., Ltd., Teva Pharmaceutical Industries Ltd., and Mylan N.V.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global chemotherapy-induced thrombocytopenia therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for dialysis market, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
- Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Drug Class:
- Thrombopoietin Receptor Agonists
- Thrombopoietic Agents
- Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Route of Administration:
- Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Distribution Channel:
- Hospital Pharmaciesa
- Retail Pharmacies
- Online Pharmacies
- Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Region:
- North America
- By Country:
- By Drug Class:
- Thrombopoietin Receptor Agonists
- Thrombopoietic Agents
- Others
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Drug Class:
- Thrombopoietin Receptor Agonists
- Thrombopoietic Agents
- Others
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Drug Class:
- Thrombopoietin Receptor Agonists
- Thrombopoietic Agents
- Others
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Drug Class:
- Thrombopoietin Receptor Agonists
- Thrombopoietic Agents
- Others
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Drug Class:
- Thrombopoietin Receptor Agonists
- Thrombopoietic Agents
- Others
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Drug Class:
- Thrombopoietin Receptor Agonists
- Thrombopoietic Agents
- Others
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Company Profiles
- Amgen, Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Novartis AG
- Pfizer Inc.
- Swedish Orphan Biovitrum AB
- Jiangsu HengRui Medicine Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
“*” marked represents similar segmentation in other categories in the respective section.
